Idioma:

Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

Segarra, R ; Recio-Barbero, M ; Sáenz-Herrero, M ; Mentxaka, O ; Cabezas-Garduño, J ; Eguíluz, J I ; Callado, L F

The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.694-702 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)
Autor: Segarra, R ; Recio-Barbero, M ; Sáenz-Herrero, M ; Mentxaka, O ; Cabezas-Garduño, J ; Eguíluz, J I ; Callado, L F
Assuntos: Administration, Oral ; Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - pharmacology ; Comparative analysis ; Delayed-Action Preparations ; Drug therapy ; Female ; Humans ; Injections ; Male ; Middle Aged ; Oral medication ; Outcome Assessment, Health Care ; Paliperidone Palmitate - administration & dosage ; Paliperidone Palmitate - pharmacology ; Psychotic Disorders - drug therapy ; Regular s ; Retrospective Studies ; Schizophrenia ; Schizophrenia - drug therapy ; Testing ; Young Adult
É parte de: The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.694-702
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Abstract Background Long-acting injectable antipsychotics (LAIs) may be a suitable therapeutic option for those patients in earlier stages of psychosis to avoid relapses and disease progression. Despite that, there is a lack of evidence in the literature regarding the use of LAIs in this profile of patients. Methods This is a retrospective cohort analysis to assess the efficacy, tolerability, and pattern of use of palmitate paliperidone long-acting injectable (PPLAI) formulations (1- and 3-month doses) compared to oral paliperidone/risperidone in patients with a nonaffective first episode of psychosis (FEP) over 12 months of follow-up. Relevant sociodemographic and clinical information were assessed, as well as main clinical scales: Positive and Negative Syndrome Scale, Personal and Social Performance Scale, and Clinical Global Impression Scale Improvement and Severity measures. Results The study included 48 patients, 16 per arm, who were aged 20–50 years and had an FEP. Significant improvements were registered for all treatment groups. Despite that, patients receiving PPLAI 1- and 3-month formulations obtained greater improvements than those in the oral group in the main domains assessed (P < .001). We found no statistically significant differences in hospitalizations between groups. Side effects were presented in 24% of patients. A trend towards reducing antipsychotic doses was observed in 43.8% of patients to achieve the minimum effective dose and avoid the occurrence of side effects. Conclusions To our knowledge, this is the first study assessing the use of palmitate paliperidone long-acting formulations versus oral risperidone or paliperidone in FEP. Treatment with PPLAI formulations seems to be an effective therapeutic choice at earlier stages of the disease.
Editor: US: Oxford University Press
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Oral and Palmitate Paliperidone Long-Acting Injectable Formulations’ Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

Segarra, R ; Recio-Barbero, M ; Sáenz-Herrero, M ; Mentxaka, O ; Cabezas-Garduño, J ; Eguíluz, J I ; Callado, L F

US: Oxford University Press

Buscando em bases de dados remotas. Favor aguardar.